DataLend: Securities lending top 10 earning equities – October 29, 2014

Securities lending top 10 earnings equities – October 29, 2014. DataLend presents its top 10 earnings equities for October 29, 2014. This list is built on DataLend’s universe of more than 42,000 securities on loan.

Methodology: We scan our universe of more than 42,000 securities on loan to find those securities with the most expensive financing positions in the U.S., U.K., Europe and Asia. Financing costs are determined by taking the total on-loan value of a security and multiplying it by the volume-weighted average fees to borrow that security, then converting the product of those numbers to a dollar value. We then sort the most expensive securities to finance in the securities lending market in descending order.

 

 

 

 

US

Utilization

1 GOPRO CL A 97.77%
2 MYRIAD GENETICS 97.25%
3 3D SYSTEMS 94.87%
4 AMTRUST FINANCIAL SERVICES 94.63%
5 DIAMOND OFFSHORE DRILLING 91.99%
6 SEARS HOLDINGS 90.13%
7 BURGER KING WORLDWIDE 95.03%
8 LINDSAY 95.38%
9 WEIGHT WATCHERS INTERNATIONAL 96.01%
10 SANDRIDGE ENERGY 96.40%

UK

Utilization

1 SAINSBURY 97.77%
2 QUINDELL 84.35%
3 MONITISE 89.19%
4 ASHMORE GROUP 80.36%
5 JSC VTB BANK GDR 58.30%
6 LONMIN 88.76%
7 BP 3.18%
8 GULF KEYSTONE PETROLEUM 63.47%
9 SAGA 11.99%
10 GLENCORE 70.90%

 

Europe

Utilization

1 GEMALTO (NL) 83.46%
2 SAINSBURY (GB) 95.44%
3 GEMALTO (FR) 96.71%
4 ROCKET INTERNET 78.77%
5 QUINDELL 50.50%
6 COMPAGNIE GENERALE GEOPHYSIQUE (FR) 88.77%
7 TRANSOCEAN (CH) 2.93%
8 TGS NOPEC GEOPHYSICAL (NO) 96.17%
9 NORWEGIAN AIR SHUTTLE (NO) 58.36%
10 ZALANDO 11.67%

 

 

Far East/Australia Pacific

Utilization

1 HANERGY TFP (HK) 89.01%
2 MIXI (JP) 96.10%
3 EVERGRANDE (HK) 86.08%
4 CELLTRION (KR) 73.62%
5 ANHUI CONCH H (HK) 72.20%
6 GUNGHO ONLINE (JP) 93.72%
7 SANRIO (JP) 87.89%
8 PRADA (HK) 90.31%
9 GREE (JP) 94.03%
10 TIANHE CHEM 87.01%

Click here for more information about DataLend’s key features.



THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

Related Posts

Previous Post
Regulating global finance: the big picture view from Andrew Haldane
Next Post
OCC securities lending CCP up 10% over Oct 2013

Fill out this field
Fill out this field
Please enter a valid email address.

X

Reset password

Create an account